CClinicalTrials.gg
CompletedNCT04333563Updated Jul 15, 2022

Non-invasive Neurally Adjusted Ventilator Assist or Continuous Positive Airway Pressure in Preterm Infants

An interventional study of CPAP and NIV NAVA in Premature Birth and Respiratory Distress Syndrome, Newborn, sponsored by St. Olavs Hospital. Completed at 1 site in Norway. Open to participants aged 24 Hours to 96 Hours. Per ClinicalTrials.gov, last updated 2022-07-15.

Sponsored by St. Olavs Hospital · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
24 Hours to 96 Hours
Sex
All
01

Study summary

Strategies to prevent lung injury, facilitate lung development, and to support the preterm infant's capacity to breathe are decisive. Continuous positive airway pressure (CPAP) is the gold standard in non-invasive breathing support in preterm infants with a positive pressure that keeps the alveoli slightly inflated during expiration. Non-invasive neurally adjusted ventilator assist (NIV NAVA) is a novel method of breathing support and uses the electrical activity from the diaphragm to trigger the ventilator and synchronize with the breathing cycle. During NIV NAVA the preterm infant controls the onset of the inspiration, the respiratory rate, inspiratory time and peak pressure. This method has the potential to improve the positive pressure transmission to the infant's lower airways, accurate synchronization with the breathing pattern and be a comfortable breathing support system for the preterm infant.

The investigators will compare the effect on breathing effort in preterm infants during continuous positive airway pressure and non-invasive neurally adjusted ventilatory assist measured by electrical activity in the diaphragm, respiratory vital signs, systematic clinical scoring of breathing effort and comfort, and parent reported outcomes.

Read the detailed description

This is a randomized cross-over study with AB/BA sequences. The infants will receive both interventions in 4 hours intervals, a 30 minutes period to change the breathing support and a 30 minutes wash out period between interventions. Initially positive end expiratory pressure are set to 5 cm H2O and can be adjusted up to 7 cm H2O if needed decided by the medical team for both interventions. The neurally adjusted level will be set to obtain average Edi peak \< 15 microvolt. Back-up setting and apnea time in the ventilator assist intervention (NIV NAVA) will be individualized according to clinical parameters in each preterm infant.

Modification approved by ethical committee REK 2021, 6th of August:

After two hours in each intervention, the nurse responsible for the infant will perform the clinical scoring. In addition it will be investigated if there is a difference in respiratory vital signs during skin to skin care and in the incubator. During each intervention period, the preterm infants are placed on the parent's chest skin to skin for at least one hour.

A modified version of the scoring tool will be used, i.e. without the item of nasal flaring and expiratory grunting. The headgear for CPAP and NIV NAVA covers parts of the nose and makes nasal flaring difficult to observe.

02

Conditions studied

  • Premature Birth
  • Respiratory Distress Syndrome, Newborn

Keywords

  • Infants, preterm
  • Respiration, Artificial
  • Diaphragm
  • Intensive Care Units, Neonatal
  • Continuous Positive Airway Pressure
  • Non invasive neurally adjusted ventilator assist
03

In context

Respiratory Distress Syndrome

1,597 studies on the registry are indexed under Respiratory Distress Syndrome; 312 are open to participants now.

This study's enrollment of 20 is below the median of 60 across 961 interventional studies indexed under Respiratory Distress Syndrome.

Browse Respiratory Distress Syndrome studies →

Lead sponsor

St. Olavs Hospital is the lead sponsor of 165 studies on the registry; 30 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
24 Hours to 96 Hours
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • spontaneously breathing preterm infants 24 to 96 hours old
  • gestational age (GA) between week 28+0 and 31+6
  • preterm infants with GA \< 28+0 with a postmenstrual age (PMA) > 28 weeks
  • at least 72 hours old treated with CPAP or NIV NAVA

Exclusion criteria

Exclusion Criteria:

  • preterm infants with severe congenital malformation
  • need for vasopressors
  • preterm children in need of a specific respiratory support system due to medical reasons
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Care provider, Outcomes assessor)
Enrollment
20 participants (actual)

Study arms

  • Active comparator
    CPAP

    respiratory stressed infants getting Continuous positive airway pressure (CPAP)

    Device: CPAP · Device: NIV NAVA

  • Experimental
    respiratory stressed infants getting NIV NAVA

    respiratory stressed infants getting Non-invasive neurally adjusted ventilatory assist (NIV NAVA)

    Device: CPAP · Device: NIV NAVA

Interventions

  • DeviceCPAP

    Continuous positive airway pressure

  • DeviceNIV NAVA

    Non-invasive neurally adjusted ventilatory assist

06

What researchers measure

Primary outcomes

  1. Electrical activity of the diaphragm

    Electromyography signals from the diaphragm in 30 second intervals

    Time frame: 9 hours and 30 minutes

Secondary outcomes

  1. Silverman Andersen Respiratory Severity Score

    The scoring tool consists of 5 categories and respiratory distress are graded from zero to two for each category. Respiratory distress gets worse the higher the total score gets.

    Time frame: Three minutes

  2. Scoring blinded for the intervention

    During each intervention, the infants will be video recorded for a blinded assessment.

    Time frame: Three minutes video-recording

  3. COMFORTneo pain scale

    Measuring pain and discomfort in a seven category scale graded from 1 - 5, where one is best and five is worse.

    Time frame: Three minutes

  4. Parents opinion about the outcomes

    Three questions about their opinion about the interventions in a 5 point Likert scale

    Time frame: Three minutes

  5. Respiratory rate

    Standard monitoring on IntelliVue monitor

    Time frame: 30 second intervals

  6. Heart rate

    Standard monitoring on IntelliVue monitor

    Time frame: 30 second intervals

  7. Oxygen saturation

    Standard monitoring on IntelliVue monitor

    Time frame: 30 second intervals

  8. number of apneic episodes ≥ 20 seconds

    Using trend function on the IntelliVue monitor

    Time frame: 9 hours and 30 seconds

07

Study locations

1 site
  • Department of Pediatrics St Olavs Hospital
    Trondheim, Norway
08

References and documents

Individual participant data

Plan to share: Yes — Study protocol Statistical analysis Informed consent form

Supporting information: Study protocol, Sap, Icf

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 15, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04333563
Lead sponsor
St. Olavs Hospital
Collaborators
Norwegian University of Science and Technology
Responsible party
Sponsor
First posted
Apr 3, 2020
Start date
Apr 14, 2020
Primary completion
Apr 30, 2022
Completion
Apr 30, 2022
Last update
Jul 15, 2022

Study contacts

Elisabeth Selvaag, md
study director · St Olavs Hospital, Barne- og ungdomsklinikk

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion